The U.S. Patent and Trademark Office (USPTO) has changed its rules governing continuing applications and Requests for Continued Examination (RCE). According to the USPTO, the changes will allow it to conduct a better and more thorough and reliable examination of patent applications. The new rules should prompt patent applicants to examine their portfolios and determine whether they should take any action before the new rules take effect on November 1, 2007.
The new rules will not have any effect on the applicant’s ability to file continuing applications before they take effect. On or after November 1, the new rules will limit applicants to two continuing applications (e.g., continuations or continuations-in-part) and a single RCE in any one application family. Applicants seeking to file additional applications exceeding these limits must petition the USPTO and show that the additional application or RCE is justified.
These new limits are a significant departure from the USPTO’s prior rules governing continuing applications and RCEs. However, the USPTO has adopted policies for the transition that will provide applicants some reprieve. The USPTO’s “one more” policy will allow applicants to file an additional continuing application, even after November 1, without requiring a petition and showing, so long as the initial application was filed prior to August 21, 2007. Any continuations or continuations-in-part filed between August 21 and November 1 will exhaust the “one more” application allowance.
The figure below illustrates the application of this policy. The initial application (I) and two continuations (C) were filed prior to August 21, 2007. The applicant is therefore permitted “one more” continuation or continuation-in-part without petition. In this example, the “one more” application was filed prior to November 1, 2007, but note that it may have been filed after that date without a petition and showing. As a result of filing the additional application, the applicant exhausted the “one more” application allowance. Any subsequent continuation application (P) requires the appropriate petition and showing.
If you have any questions about the USPTO’s rules, or their effect on your patent portfolio, please contact the Intellectual Property Group at Benesch Friedlander Coplan & Aronoff LLP.
Latest News
Medical First, Recreational Later? DOJ’s Cannabis Order and the Stakes Ahead
DOJ’s April 2026 order immediately moved FDA-approved and state-licensed medical cannabis to Schedule III, removing harsh tax penalties for medical operators, while leaving adult-use cannabis under stricter Schedule I controls pending further administrative review.
New Sentencing Guidelines for Economic Crimes Effective November 1, 2026
In March we reported on the U.S. Sentencing Commission’s proposed amendments to the Federal Sentencing Guidelines (the “Guidelines”). On April 16, 2026, the bipartisan United States Sentencing Commission (the “Commission”) voted unanimously to adopt that package of amendments, without modification.
Judicial Green Light: Court Upholds NLRB’s Cemex Decision
On April 21st, 2026, the U.S. Court of Appeals for the Ninth Circuit upheld the National Labor Relations Board’s (“NLRB”) decision in Cemex Construction Materials Pacific, LLC., reinforcing a significant shift in federal labor law governing union recognition and employer conduct during organizing campaigns.
The LEAD Model—Kidney Care’s Value-Based Care Journey LEADs Here
The new LEAD Model, launching in 2027, is CMS’s next-generation value-based care framework for kidney care, integrating CKD and ESRD patients into standard ACOs with a 10-year benchmark period, new payment options and greater flexibility for nephrology-led organizations.